

Ivabradine (hydrochloride)

Catalog No: tcsc1994

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg

Specifications

CAS No:

148849-67-6

Formula:

 $C_{27}H_{37}CIN_2O_5$

Pathway: GPCR/G Protein

Target: Adrenergic Receptor

Purity / Grade:

>98%

Solubility:

 $DMSO : \ge 51 \text{ mg/mL} (100.98 \text{ mM})$

Observed Molecular Weight:

505.05

Product Description

Ivabradine (hydrochloride) is a new I_f inhibitor with IC₅₀ of 2.9 μ M, and used as a pure heart rate lowering agent.

Copyright 2021 Taiclone Biotech Corp.



In Vivo: Ivabradine treatment (10 mg/kg/d) induces long-term HRR, and that improves diastolic LV function probably involving attenuated hypoxia, reduced remodeling, and/or preserved nitric oxide bioavailability, resulting from processes triggered early after HRR initiation: angiogenesis and/or preservation of endothelial nitric oxide synthase expression^[1]. Ivabradine leads to a sustained 15-20% heart rate reduction, but has no effect on blood pressure. While ivabradine has no effect on endothelial function and vascular reactive oxygen species production in angiotensin II-treated rats, it improves both parameters in ApoE knockout mice. Ivabradine treatment leads to an attenuation of angiotensin II signaling and increased the expression of telomere-stabilizing proteins in ApoE knockout mice, which may explain its beneficial effects on the vasculature. The absence of these protective ivabradine effects in angiotensin II-infused rats may relate to the treatment duration or the presence of arterial hypertension^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!

Copyright 2021 Taiclone Biotech Corp.